KR102170674B1 - Fc 감마 수용체 IIB 변이체 - Google Patents

Fc 감마 수용체 IIB 변이체 Download PDF

Info

Publication number
KR102170674B1
KR102170674B1 KR1020157013516A KR20157013516A KR102170674B1 KR 102170674 B1 KR102170674 B1 KR 102170674B1 KR 1020157013516 A KR1020157013516 A KR 1020157013516A KR 20157013516 A KR20157013516 A KR 20157013516A KR 102170674 B1 KR102170674 B1 KR 102170674B1
Authority
KR
South Korea
Prior art keywords
protein
seq
ser
host cell
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157013516A
Other languages
English (en)
Korean (ko)
Other versions
KR20150122621A (ko
Inventor
피터 존더만
도미니크 터 미어
토마스 폴
레노 빈터
우베 야콥
Original Assignee
수프레몰 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 수프레몰 게엠베하 filed Critical 수프레몰 게엠베하
Publication of KR20150122621A publication Critical patent/KR20150122621A/ko
Application granted granted Critical
Publication of KR102170674B1 publication Critical patent/KR102170674B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
KR1020157013516A 2012-10-30 2013-10-30 Fc 감마 수용체 IIB 변이체 Active KR102170674B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/663,527 2012-10-30
US13/663,527 US10028998B2 (en) 2012-10-30 2012-10-30 Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
PCT/EP2013/072741 WO2014068012A1 (en) 2012-10-30 2013-10-30 Fc gamma receptor iib variants

Publications (2)

Publication Number Publication Date
KR20150122621A KR20150122621A (ko) 2015-11-02
KR102170674B1 true KR102170674B1 (ko) 2020-10-28

Family

ID=49679480

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157013516A Active KR102170674B1 (ko) 2012-10-30 2013-10-30 Fc 감마 수용체 IIB 변이체

Country Status (27)

Country Link
US (1) US10028998B2 (https=)
EP (1) EP2914624B1 (https=)
JP (2) JP6423351B2 (https=)
KR (1) KR102170674B1 (https=)
CN (1) CN104918955B (https=)
AU (1) AU2013340831B2 (https=)
BR (1) BR112015008815A2 (https=)
CA (1) CA2887164C (https=)
CL (1) CL2015001127A1 (https=)
DK (1) DK2914624T3 (https=)
EA (1) EA033437B9 (https=)
ES (1) ES2628049T3 (https=)
HR (1) HRP20170894T1 (https=)
HU (1) HUE032786T2 (https=)
IL (1) IL238528A (https=)
IN (1) IN2015DN03206A (https=)
LT (1) LT2914624T (https=)
MX (1) MX359802B (https=)
MY (1) MY173686A (https=)
NZ (1) NZ706884A (https=)
PH (1) PH12015500771B1 (https=)
PL (1) PL2914624T3 (https=)
PT (1) PT2914624T (https=)
RS (1) RS56075B1 (https=)
SG (1) SG11201502749VA (https=)
SI (1) SI2914624T1 (https=)
WO (1) WO2014068012A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
EP2796144A1 (en) * 2013-04-26 2014-10-29 SuppreMol GmbH Highly concentrated Formulations of soluble Fc receptors
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
CN105873600B (zh) * 2013-10-16 2019-11-05 苏伯利莫尔公司 用于自身免疫性大疱病治疗的可溶性Fcγ受体
JP6710451B2 (ja) * 2016-03-31 2020-06-17 東ソー株式会社 改変型組換えＦｃγＲＩＩｂ
US20210260611A1 (en) * 2018-06-25 2021-08-26 Basf Coatings Gmbh Method for producing an optimized coating, and coating which can be obtained using said method
CN111454914A (zh) * 2019-01-18 2020-07-28 嘉兴安宇生物科技有限公司 一种腺病毒快速纯化方法
WO2024092031A1 (en) 2022-10-25 2024-05-02 Seismic Therapeutic, Inc. VARIANT IgG FC POLYPEPTIDES AND USES THEREOF

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002924A1 (en) * 2001-11-22 2005-01-06 Robert Huber Pharmaceutical composition containing sFcgammaR IIb or sFcgammaR III

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2164088C (en) 1993-06-07 2005-06-14 Gary J. Nabel Plasmids suitable for gene therapy
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2004293184B2 (en) 2003-11-26 2010-12-16 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Substance binding human IgG Fc receptor IIb
WO2007068047A1 (en) 2005-12-13 2007-06-21 Trillium Therapeutics Inc Multimeric fc receptor polypeptides
EP1870442A1 (en) * 2006-06-19 2007-12-26 DSMIP Assets B.V. Air drying resin and composition
EP1870422A1 (en) 2006-06-20 2007-12-26 SuppreMol GmbH Means for the treatment of diseases characterized by an excessive immune reaction
JP2011526154A (ja) 2008-06-27 2011-10-06 ザイモジェネティクス， インコーポレイテッド 可溶性ハイブリッドＦｃγレセプターおよび関連する方法
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002924A1 (en) * 2001-11-22 2005-01-06 Robert Huber Pharmaceutical composition containing sFcgammaR IIb or sFcgammaR III

Also Published As

Publication number Publication date
IL238528A0 (en) 2015-06-30
CN104918955B (zh) 2018-10-09
MX359802B (es) 2018-10-10
AU2013340831A1 (en) 2015-04-30
MX2015005266A (es) 2015-10-26
IL238528A (en) 2017-07-31
LT2914624T (lt) 2017-06-26
JP2016503289A (ja) 2016-02-04
PL2914624T3 (pl) 2017-09-29
EA033437B1 (ru) 2019-10-31
CA2887164C (en) 2020-12-29
EP2914624A1 (en) 2015-09-09
IN2015DN03206A (https=) 2015-10-02
WO2014068012A1 (en) 2014-05-08
SI2914624T1 (sl) 2017-07-31
HRP20170894T1 (hr) 2017-09-08
EA201590845A1 (ru) 2015-08-31
EA033437B9 (ru) 2020-03-19
SG11201502749VA (en) 2015-05-28
CN104918955A (zh) 2015-09-16
BR112015008815A2 (pt) 2017-11-21
MY173686A (en) 2020-02-15
PT2914624T (pt) 2017-06-07
AU2013340831B2 (en) 2017-11-23
US20140120080A1 (en) 2014-05-01
KR20150122621A (ko) 2015-11-02
PH12015500771B1 (en) 2018-12-14
CA2887164A1 (en) 2014-05-08
RS56075B1 (sr) 2017-10-31
DK2914624T3 (en) 2017-06-26
HK1209765A1 (en) 2016-04-08
PH12015500771A1 (en) 2015-06-08
HUE032786T2 (en) 2017-10-30
NZ706884A (en) 2019-05-31
JP6423351B2 (ja) 2018-11-14
EP2914624B1 (en) 2017-03-15
CL2015001127A1 (es) 2015-12-18
US10028998B2 (en) 2018-07-24
JP2018186833A (ja) 2018-11-29
ES2628049T3 (es) 2017-08-01

Similar Documents

Publication Publication Date Title
KR102170674B1 (ko) Fc 감마 수용체 IIB 변이체
US20230293644A1 (en) Anti-inflammatory peptides and composition comprising the same
KR101516023B1 (ko) 눈물 리포칼린 돌연변이 단백질 및 이를 얻는 방법
KR101871510B1 (ko) 액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
CN108350467B (zh) 基因构建体
Wu et al. Huntingtin-associated protein-1 interacts with pro-brain-derived neurotrophic factor and mediates its transport and release
TW200848071A (en) Immunoglobulin fusion proteins and methods of making
KR20140099526A (ko) 안구 건조증의 치료를 위한 jnk 신호 전달 경로의 세포-투과성 펩타이드 억제자의 용도
US20230414777A1 (en) Antigen Presenting Polypeptide Complexes and Methods of Use Thereof
JP2020191860A (ja) Ｉｌ−３７バリアント
JP2018535964A (ja) 線維芽細胞増殖因子（ｆｇｆ）１アナログによるステロイド誘導性高血糖の処置
US10669324B2 (en) Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
KR102184377B1 (ko) 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
CA2735085C (en) Fc gamma iib receptor for the treatment of b cell mediated multiple sclerosis
Lepage et al. The self-association of two N-terminal interaction domains plays an important role in the tetramerization of TRPC4
CN115989238A (zh) 包含il-2蛋白和cd80蛋白片段或其变体的融合蛋白及其用途
HK1209765B (en) Fc gamma receptor iib variants
KR102256267B1 (ko) 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
KR102365266B1 (ko) 미나리 유래 폴리펩티드 및 상기 폴리펩티드를 포함하는 약학적 조성물
LT4877B (lt) Prv-1 genas ir jo panaudojimas
WO2025111562A1 (en) Mhc class ii protein complexes
WO2026050634A1 (en) Butyrophilin a2 for inhibition of b cell activation and/or for prolonged humoral suppression or humoral tolerance
KR20210141406A (ko) 신규 재조합 융합단백질 및 그의 용도
JP2002233365A (ja) クローンｈｗｈｈｊ２０

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150522

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20181017

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200207

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200901

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20201021

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20201021

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240220

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20241015

Start annual number: 5

End annual number: 5